Definition, Classification and Diagnosis of Diabetes Mellitus

Schleicher, Erwin; Gerdes, Christian; Petersmann, Astrid; Müller‐Wieland, Dirk; Müller, Ulrich; Freckmann, Guido; Heinemann, Lutz; Nauck, Matthias; Landgraf, R.

doi:10.1055/a-1624-2897

Cited by 48 publications

(36 citation statements)

References 18 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A prediabetic state was defined by impaired fasting glucose (fasting glucose 100 to 125 mg/dl (5.6–6.9 mmol/l)) (IGT) and/or impaired glucose tolerance (IGT and 2-h post-load plasma glucose 140–199 mg/dl (7.8–11.0 mmol/l) during the study visit. Patients with glucose levels within the physiological/prediabetic spectrum and HbA1c levels ranging from 6.5 to 7% were not considered as diabetic [ 24 ].…”

Section: Methodsmentioning

confidence: 99%

Secondary prevention in diabetic and nondiabetic coronary heart disease patients: Insights from the German subset of the hospital arm of the EUROASPIRE IV and V surveys

et al. 2022

View full text Add to dashboard Cite

Background Patients with coronary heart disease (CHD) with and without diabetes mellitus have an increased risk of recurrent events requiring multifactorial secondary prevention of cardiovascular risk factors. We compared prevalences of cardiovascular risk factors and its determinants including lifestyle, pharmacotherapy and diabetes mellitus among patients with chronic CHD examined within the fourth and fifth EUROASPIRE surveys (EA-IV, 2012–13; and EA-V, 2016–17) in Germany. Methods The EA initiative iteratively conducts European-wide multicenter surveys investigating the quality of secondary prevention in chronic CHD patients aged 18 to 79 years. The data collection in Germany was performed during a comprehensive baseline visit at study centers in Würzburg (EA-IV, EA-V), Halle (EA-V), and Tübingen (EA-V). Results 384 EA-V participants (median age 69.0 years, 81.3% male) and 536 EA-IV participants (median age 68.7 years, 82.3% male) were examined. Comparing EA-IV and EA-V, no relevant differences in risk factor prevalence and lifestyle changes were observed with the exception of lower LDL cholesterol levels in EA-V. Prevalence of unrecognized diabetes was significantly lower in EA-V as compared to EA-IV (11.8% vs. 19.6%) while the proportion of prediabetes was similarly high in the remaining population (62.1% vs. 61.0%). Conclusion Between 2012 and 2017, a modest decrease in LDL cholesterol levels was observed, while no differences in blood pressure control and body weight were apparent in chronic CHD patients in Germany. Although the prevalence of unrecognized diabetes decreased in the later study period, the proportion of normoglycemic patients was low. As pharmacotherapy appeared fairly well implemented, stronger efforts towards lifestyle interventions, mental health programs and cardiac rehabilitation might help to improve risk factor profiles in chronic CHD patients.

show abstract

Section: Methodsmentioning

confidence: 99%

Secondary prevention in diabetic and nondiabetic coronary heart disease patients: Insights from the German subset of the hospital arm of the EUROASPIRE IV and V surveys

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Conversion of capillary measured values into venous values is not permitted. Blood glucose measurements for GDM diagnostics must meet For detailed information on pre-analytics, methodology and evaluation for the determination of plasma glucose and HbA1c, please refer to the DDG's recommendation "Definition, classification and diagnosis of diabetes mellitus" [1].…”

Section: Blood Samples and Measurement Quality Requirementsmentioning

confidence: 99%

Gestational Diabetes Mellitus (GDM), Diagnostics, Therapy and Follow-up Care

Schäfer‐Graf

Laubner

Hummel

et al. 2023

Exp Clin Endocrinol Diabetes

View full text Add to dashboard Cite

The DDG practice recommendations are updated regularly during the second half of the calendar year. Please ensure that you read and cite the respective current version. Preliminary noteThis practice guideline on gestational diabetes is a practical summary of the evidence-based S3 guideline available on the Internet (https://www.awmf.org/uploads/tx_szleitlinien/057-008p_S3_ Gestationsdiabetes-mellitus-GDM-Diagnostik-Therapie-Nach-sorge_2020-01.pdf), published by the German Diabetes Society (Deutsche Diabetes Gesellschaft -DDG) and the German Society for Gynecology and Obstetrics (Deutsche Gesellschaft für Gynäko-This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.

show abstract

“…The development of this disease is often linked to obesity, family history, a sedentary lifestyle, and old age. 23 Hibiscus spp.…”

Section: Type 2 Diabetes Mellitusmentioning

confidence: 99%

Anti-diabetic effects of Hibiscus spp. extract in rat and mice models: A review

Viado

Purnamasari

Cruz

2022

JGI

View full text Add to dashboard Cite

Diabetes mellitus, a chronic metabolic disease characterized by sustained hyperglycemia, has become a worldwide concern due to the upward trend of recorded cases each passing year. It is one of the leading causes of death in the world. Medication for the management and treatment of diabetes is neither affordable nor accessible in most parts of the Philippines thus raising the need for cost-effective alternatives. Plant extracts have long been used as a treatment for a variety of diseases. One of the plants to display biological activity is Hibiscus spp. It is used to treat a variety of diseases and has steadily gained recognition for its anti-diabetic properties. Several of its plant parts such as the leaves, flowers, and calyces had been used in laboratory models of type 1 and 2 diabetes mellitus. However, methods of extracting biologically active components of the plant vary and yield different results depending upon the concentration and temperature of the extraction procedure. Furthermore, it has shown hypoglycemic effects comparable to commonly used drugs in the treatment of diabetes such as metformin and glibenclamide. Although these studies suggest the efficacy of Hibiscus spp. extract as an antidiabetic agent, it still warrants further clinical trials to establish its efficacy and limitations.

show abstract

Definition, Classification and Diagnosis of Diabetes Mellitus

Cited by 48 publications

References 18 publications

Secondary prevention in diabetic and nondiabetic coronary heart disease patients: Insights from the German subset of the hospital arm of the EUROASPIRE IV and V surveys

Secondary prevention in diabetic and nondiabetic coronary heart disease patients: Insights from the German subset of the hospital arm of the EUROASPIRE IV and V surveys

Gestational Diabetes Mellitus (GDM), Diagnostics, Therapy and Follow-up Care

Anti-diabetic effects of Hibiscus spp. extract in rat and mice models: A review

Contact Info

Product

Resources

About